Company News

Globally, it was estimated that approximately 4.95 million people died from Antimicrobial Resistance-related causes in 20191. And yet, one in three adults doesn’t understand what this term means2. Faced with this alarming situation, an awareness-raising campaign encourages the general public to change their behaviour with regard to the use of antibiotics. Indeed, each person, at their own level, has a role to play to preserve their effectiveness.

bioMérieux, a world leader in the field of in vitro diagnostics, signed in November 2024 a Sale and Purchase Agreement (SPA) to acquire Neoprospecta. This company, based in Florianopolis, Brazil, develops and markets innovative user-friendly data and genomics solutions for augmenting quality assurance programs and improve microbiological risk prevention in food and pharma industries.

On the sidelines of the 2024 United Nations High-Level Meeting on Antimicrobial Resistance (AMR), a multisectoral event titled “Advancing Together: Securing the Global AMR Agenda by Harnessing the Collective Strength of Multi-Sector Partnerships” took place on September 24 in New York. bioMérieux, in partnership with The Wellcome Trust, The American Society of Microbiology, Malawi, and the French Republic, organized the event to focus on fostering a collaborative ecosystem that establishes sustainable solutions across the entire AMR landscape. From diagnosis and treatment to surveillance and action plans, this initiative spanned human health, animals, and the environment.

bioMérieux, a world leader in in vitro diagnostics, celebrated the opening of the company’s Molecular Genomic Innovation Center in Philadephia, PA, on September 18th. The new 32,000 sq. ft. facility is home to the xPRO™ Program, which has rapidly changed the landscape of food safety diagnostic capabilities by partnering directly with industry leaders to address unmet needs to streamline operational efficiencies and further public health.

bioMérieux, a world leader in in vitro diagnostics, celebrates the opening of the company’s Molecular & Genomic Innovation Center. The new 32,000 sq. ft. facility is home to the xPRO™ Program, which has rapidly changed the landscape of food safety diagnostic capabilities by partnering directly with industry leaders to address unmet needs to streamline operational efficiencies and further public health.